Финам

      Sanara MedTech Inc.

      Sanara MedTech Inc.

      SMTI
      BATS
      Акции

      31,45 $

      -0,14 $

      -0,43%

      Обновлено 19 авг. 17:25

      23,53 $

      39,08 $

      Мин./макс. за год

      О компании

      Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

      Капитализация

      281,14 млн $

      Кол-во акций

      8,90 млн

      Сектор

      Здравоохранение

      Отрасль

      Медицинское оборудование и снабжение

      ISIN

      US79957L1008

      Размер лота

      100

      Веб-сайт

      sanaramedtech.com